产品
编 号：F334585
分子式：C21H21N5
分子量：343.42
分子式：C21H21N5
分子量：343.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
185
In-stock
5mg
408
In-stock
10mg
664
In-stock
50mg
2504
In-stock
100mg
3840
In-stock
结构图
CAS No: 356559-20-1
产品详情
生物活性：
SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
体内研究：
SB525334 (3-30 mg/kg; p.o.; daily from days 17 to 35) significantly reverses pulmonary arterial pressure in a rat model of pulmonary arterial hypertension (PAH).Animal Model:Adult male Sprague-Dawley rats (MCT rat model of pulmonary hypertension)
Dosage:3, 30 mg/kg
Administration:Oral administration; daily from days 17 to 35
Result:Reduced the proportion of fully muscularized vessels to 28% at 3 mg/kg and returned fully muscularized vessel distribution beyond that seen at day 17 and approaching the phenotype observed in saline-exposed controls at 30 mg/kg.
体外研究：
SB525334 (1 μM; for 15 minutes before stimulating with 0.625 ng/ml of TGF-β1, assesses after 6 days) inhibits TGF-β1-mediated proliferation of familial idiopathic pulmonary arterial hypertension (iPAH) pulmonary artery smooth muscle cells (PASMCs) at an IC50 of 295 nM .
SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
体内研究：
SB525334 (3-30 mg/kg; p.o.; daily from days 17 to 35) significantly reverses pulmonary arterial pressure in a rat model of pulmonary arterial hypertension (PAH).Animal Model:Adult male Sprague-Dawley rats (MCT rat model of pulmonary hypertension)
Dosage:3, 30 mg/kg
Administration:Oral administration; daily from days 17 to 35
Result:Reduced the proportion of fully muscularized vessels to 28% at 3 mg/kg and returned fully muscularized vessel distribution beyond that seen at day 17 and approaching the phenotype observed in saline-exposed controls at 30 mg/kg.
体外研究：
SB525334 (1 μM; for 15 minutes before stimulating with 0.625 ng/ml of TGF-β1, assesses after 6 days) inhibits TGF-β1-mediated proliferation of familial idiopathic pulmonary arterial hypertension (iPAH) pulmonary artery smooth muscle cells (PASMCs) at an IC50 of 295 nM .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备